- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.11. | Sight Sciences Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| SIGHT SCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.11. | Sight Sciences, Inc.: Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations | 2 | GlobeNewswire (USA) | ||
| 07.11. | Sight Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Sight Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.10. | Sight Sciences, Inc.: Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 | 2 | GlobeNewswire (USA) | ||
| 15.10. | Sight Sciences: TearCare Treatment Enhances Visual Outcomes And Symptoms In Dry Eye Disease Trial | 1 | RTTNews | ||
| 14.10. | Sight Sciences, Inc.: Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial | 1 | GlobeNewswire (USA) | ||
| 04.10. | Lake Street bekräftigt Kaufempfehlung für Sight Sciences-Aktien aufgrund des Wachstumspotenzials | 1 | Investing.com Deutsch | ||
| 04.10. | Sight Sciences shares reiterate Buy rating from Lake Street on growth potential | 1 | Investing.com | ||
| 26.09. | Sight Sciences gains Medicare coverage for eye surgery tech | 1 | Investing.com | ||
| 26.09. | Sight Sciences erhält Medicare-Abdeckung für Augenoperationstechnologie | 1 | Investing.com Deutsch | ||
| 26.09. | Sight Sciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 20.08. | Sight Sciences, Inc.: Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 02.08. | Sight Sciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.08. | Sight Sciences GAAP EPS of -$0.25 beats by $0.04, revenue of $21.4M beats by $0.05M | 1 | Seeking Alpha | ||
| 01.08. | Sight Sciences, Inc.: Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance | 157 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing... ► Artikel lesen | |
| 18.07. | Sight Sciences, Inc.: Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 | 1 | GlobeNewswire (USA) | ||
| 10.07. | CVRx plunges, Sight Sciences jumps on proposed Medicare rate changes | 1 | Seeking Alpha | ||
| 10.06. | Sight Sciences, Inc.: Sight Sciences Announces the Release of its First Sustainability Report | 1 | GlobeNewswire (USA) | ||
| 30.05. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EMEIS | 5,705 | +1,44 % | emeis: Upturn in Performance Confirmed in Third-Quarter 2024 | Revenue up +8.3%, occupancy rate up +2.6 points
Regulatory News:
emeis (Paris:EMEIS):
Growth in all core activities and in all geographical areas (revenue and occupancy rate)
Solid... ► Artikel lesen | |
| NANO-X IMAGING | 5,890 | 0,00 % | Nano-X Imaging LTD.: Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium | HealthCCSng V2.0 introduces additional 'zero calcium' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output Marks... ► Artikel lesen | |
| BUTTERFLY NETWORK | 3,325 | 0,00 % | BFLY-Aktie erreicht 52-Wochen-Hoch bei 2,95 US-Dollar | ||
| GOODRX | 4,310 | 0,00 % | GoodRx Holdings one of the most undervalued stocks, Leerink says | ||
| TALKSPACE | 3,160 | 0,00 % | Espresa Partners with Talkspace to Boost Employee Well-Being with Accessible Mental Health Benefits | Espresa has partnered with Talkspace to expand mental health support for employees. Through Espresa's platform, clients now have access to Talkspace's 5,000+ licensed therapists, offering secure, on-demand... ► Artikel lesen | |
| CARMAT | 1,190 | -1,00 % | CARMAT's Aeson Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe | Milestone of 30 heart transplants post Aeson® support, passed Strong interest in Aeson® from the medical community: more than 100 European experts will share their experience at the first... ► Artikel lesen | |
| JOINT CORP | 11,310 | 0,00 % | JYNT's Q3 Earnings Meet Estimates Amid Higher Costs, Shares Dip 3% | ||
| MIMEDX | 9,070 | 0,00 % | MIMEDX GROUP, INC. - 8-K, Current Report | ||
| HYPERFINE | 0,900 | 0,00 % | Hyperfine, Inc. Reports Third Quarter 2024 Financial Results | GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 92,70 | 0,00 % | Looking Into PROCEPT BioRobotics' Recent Short Interest | ||
| BIOMERICA | 0,320 | 0,00 % | Biomerica, Inc.: Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements | IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day... ► Artikel lesen | |
| PROGYNY | 13,980 | 0,00 % | Barclays Lowers Progyny (NASDAQ:PGNY) Price Target to $17.00 | ||
| ATRICURE | 36,030 | 0,00 % | Pre-market Movers: ASP Isotopes, NerdWallet, Reddit, AtriCure, Qorvo | OLATHE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green ASP Isotopes Inc. (ASPI) is up over 44% at $8.33.
NerdWallet... ► Artikel lesen | |
| LIFEMD | 5,400 | 0,00 % | LifeMD, Inc.: LifeMD Reports Third Quarter 2024 Results | Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65%Record gross margin of 90.6%, up 300 basis points from the year-ago periodAdjusted EBITDA increased 33% to... ► Artikel lesen | |
| PROPHASE LABS | 0,690 | +0,73 % | ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2024 Earnings Call Transcript |
Das Unternehmen SIGHT SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 3,750 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIGHT SCIENCES INC finden Sie auf Wallstreet Online.
